Sign in to view content

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Caroline Baumal, MD, FASRS

Video
Published 2021

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
Intermittent to Continuous Therapy for Diabetic Macular Edema leads to Reduction in Treatment Frequency and Reduced Retinal Thickness Fluctuations
Seenu M. Hariprasad, MD
On Demand Cases, Courses, and Papers
2019
ASRS Updates in the Management of Diabetic Retinopathy DME and PDR in the Middle East and Africa
Sunir J. Garg, MD, FACS, FASRS
Webinars and Journal Clubs
2023

Category: Diabetic Retinopathy

See more